Latest Information Update: 09 Sep 2003
At a glance
- Originator Novuspharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Sep 2003 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 24 Oct 2001 Preclinical development for Cancer in Italy (Unknown route)